

Nienke Biermasz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/391192/publications.pdf>

Version: 2024-02-01

263
papers

12,222
citations

22146

59
h-index

36025

97
g-index

273
all docs

273
docs citations

273
times ranked

9127
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality in Acromegaly: A Metaanalysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 61-67.	3.6	464
2	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 847-875.	11.4	315
3	A Single Night of Partial Sleep Deprivation Induces Insulin Resistance in Multiple Metabolic Pathways in Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2963-2968.	3.6	301
4	Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. <i>Pituitary</i> , 2012, 15, 71-83.	2.9	274
5	Survival and Death Causes in Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 313-319.	3.6	248
6	Quality of Life in Patients after Long-Term Biochemical Cure of Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3279-3286.	3.6	225
7	Decreased Quality of Life in Patients with Acromegaly Despite Long-Term Cure of Growth Hormone Excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5369-5376.	3.6	213
8	Detrimental effects of constant light exposure and high-fat diet on circadian energy metabolism and insulin sensitivity. <i>FASEB Journal</i> , 2013, 27, 1721-1732.	0.5	213
9	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e937-e946.	3.6	207
10	Mortality in Patients Treated for Cushing's Disease Is Increased, Compared with Patients Treated for Nonfunctioning Pituitary Macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 976-981.	3.6	201
11	Sleep characteristics across the lifespan in 1.1 million people from the Netherlands, United Kingdom and United States: a systematic review and meta-analysis. <i>Nature Human Behaviour</i> , 2021, 5, 113-122.	12.0	193
12	Determinants of Survival in Treated Acromegaly in a Single Center: Predictive Value of Serial Insulin-Like Growth Factor I Measurements. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2789-2796.	3.6	188
13	Multidisciplinary management of acromegaly: A consensus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 667-678.	5.7	183
14	High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. <i>Clinical Endocrinology</i> , 2005, 62, 197-204.	2.4	182
15	Morbidity after Long-Term Remission for Acromegaly: Persisting Joint-Related Complaints Cause Reduced Quality of Life. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2731-2739.	3.6	182
16	Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. <i>Nature Genetics</i> , 2012, 44, 1375-1381.	21.4	169
17	Ten-Year Follow-Up Results of Transsphenoidal Microsurgery in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4596-4602.	3.6	164
18	Long-Term Predictive Value of Postsurgical Cortisol Concentrations for Cure and Risk of Recurrence in Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5858-5864.	3.6	161

#	ARTICLE	IF	CITATIONS
19	Long-Term Follow-Up Results of Postoperative Radiotherapy in 36 Patients with Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2476-2482.	3.6	155
20	The Suprachiasmatic Nucleus Controls Circadian Energy Metabolism and Hepatic Insulin Sensitivity. <i>Diabetes</i> , 2013, 62, 1102-1108.	0.6	152
21	Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. <i>Clinical Endocrinology</i> , 2008, 69, 775-784.	2.4	148
22	Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1699-1708.	3.6	144
23	MECHANISMS IN ENDOCRINOLOGY: Cushing's syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. <i>European Journal of Endocrinology</i> , 2015, 173, R1-R14.	3.7	141
24	Subtle Cognitive Impairments in Patients with Long-Term Cure of Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2699-2714.	3.6	140
25	Meta-Analysis and Dose-Response Metaregression: Circulating Insulin-Like Growth Factor I (IGF-I) and Mortality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2912-2920.	3.6	131
26	Partial Sleep Restriction Decreases Insulin Sensitivity in Type 1 Diabetes. <i>Diabetes Care</i> , 2010, 33, 1573-1577.	8.6	126
27	Pituitary Dysfunction in Adult Patients after Cranial Radiotherapy: Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2330-2340.	3.6	126
28	High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. <i>European Journal of Endocrinology</i> , 2011, 164, 475-483.	3.7	125
29	Increased Prevalence of Psychopathology and Maladaptive Personality Traits after Long-Term Cure of Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E129-E141.	3.6	121
30	Prolonged daily light exposure increases body fat mass through attenuation of brown adipose tissue activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 6748-6753.	7.1	115
31	Hypopituitarism following traumatic brain injury: prevalence is affected by the use of different dynamic tests and different normal values. <i>European Journal of Endocrinology</i> , 2010, 162, 11-18.	3.7	112
32	Quality of Life Is Decreased after Treatment for Nonfunctioning Pituitary Macroadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3364-3369.	3.6	111
33	Quality of life in treated adult craniopharyngioma patients. <i>European Journal of Endocrinology</i> , 2006, 154, 483-489.	3.7	103
34	Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. <i>Pituitary</i> , 2015, 18, 752-776.	2.9	95
35	Growth Hormone (GH) Secretion in Patients with an Inactivating Defect of the GH-Releasing Hormone (GHRH) Receptor Is Pulsatile: Evidence for a Role for Non-GHRH Inputs into the Generation of GH Pulses. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2459-2464.	3.6	94
36	Impact of the Exon 3-Deleted Growth Hormone (GH) Receptor Polymorphism on Baseline Height and the Growth Response to Recombinant Human GH Therapy in GH-Deficient (GHD) and Non-GHD Children with Short Stature: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3721-3730.	3.6	90

#	ARTICLE	IF	CITATIONS
37	Smaller grey matter volumes in the anterior cingulate cortex and greater cerebellar volumes in patients with long-term remission of Cushing's disease: a case-control study. <i>European Journal of Endocrinology</i> , 2013, 169, 811-819.	3.7	84
38	Preoperative risk factors for postoperative complications in endoscopic pituitary surgery: a systematic review. <i>Pituitary</i> , 2018, 21, 84-97.	2.9	84
39	The IGSF1 Deficiency Syndrome: Characteristics of Male and Female Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4942-4952.	3.6	81
40	Physiological control of pituitary hormone secretory-burst mass, frequency, and waveform: a statistical formulation and analysis. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2003, 285, R664-R673.	1.8	80
41	The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. <i>European Journal of Endocrinology</i> , 2007, 156, 455-462.	3.7	80
42	Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e32-e41.	3.6	78
43	Negative illness perceptions are associated with impaired quality of life in patients after long-term remission of Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2011, 165, 527-535.	3.7	77
44	Widespread reductions of white matter integrity in patients with long-term remission of Cushing's disease. <i>NeuroImage: Clinical</i> , 2014, 4, 659-667.	2.7	76
45	Therapy of Endocrine disease: Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. <i>European Journal of Endocrinology</i> , 2013, 169, R1-R14.	3.7	74
46	Poor sleep quality and later sleep timing are risk factors for osteopenia and sarcopenia in middle-aged men and women: The NEO study. <i>PLoS ONE</i> , 2017, 12, e0176685.	2.5	74
47	Mutations in <i>TBL1X</i> Are Associated With Central Hypothyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4564-4573.	3.6	73
48	Endoscopic vs. microscopic transsphenoidal surgery for Cushing's disease: a systematic review and meta-analysis. <i>Pituitary</i> , 2018, 21, 524-534.	2.9	71
49	High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case-control study. <i>European Journal of Endocrinology</i> , 2009, 160, 357-365.	3.7	70
50	Affected Illness Perceptions and the Association with Impaired Quality of Life in Patients with Long-Term Remission of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3550-3558.	3.6	69
51	A Diurnal Rhythm in Brown Adipose Tissue Causes Rapid Clearance and Combustion of Plasma Lipids at Wakening. <i>Cell Reports</i> , 2018, 22, 3521-3533.	6.4	68
52	Coping Strategies in Patients after Treatment for Functioning or Nonfunctioning Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 964-971.	3.6	67
53	Opioids and Their Endocrine Effects: A Systematic Review and Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1020-1029.	3.6	66
54	Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. <i>European Journal of Endocrinology</i> , 2004, 150, 489-495.	3.7	65

#	ARTICLE	IF	CITATIONS
55	Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly. <i>Clinical Endocrinology</i> , 2008, 69, 123-128.	2.4	65
56	Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. <i>Clinical Endocrinology</i> , 2000, 53, 321-327.	2.4	63
57	Increased Psychopathology and Maladaptive Personality Traits, But Normal Cognitive Functioning, In Patients after Long-Term Cure of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E392-E402.	3.6	63
58	Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters. <i>Frontiers in Endocrinology</i> , 2017, 8, 40.	3.5	63
59	Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2012, 166, 27-34.	3.7	62
60	Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration. <i>Nature Communications</i> , 2019, 10, 5121.	12.8	62
61	Effects of Dehydroepiandrosterone, Superimposed on Growth Hormone Substitution, on Quality of Life and Insulin-Like Growth Factor I in Patients with Secondary Adrenal Insufficiency: A Randomized, Placebo-Controlled, Cross-Over Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3295-3303.	3.6	61
62	Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: cross-sectional study and review of the literature. <i>European Journal of Endocrinology</i> , 2014, 171, 171-182.	3.7	61
63	Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis. <i>Pituitary</i> , 2018, 21, 631-641.	2.9	61
64	Bone and Joint Disorders in Acromegaly. <i>Neuroendocrinology</i> , 2016, 103, 86-95.	2.5	60
65	A tale of pituitary adenomas: to NET or not to NET. <i>Pituitary</i> , 2019, 22, 569-573.	2.9	60
66	Low prevalence of hypopituitarism after traumatic brain injury: a multicenter study. <i>European Journal of Endocrinology</i> , 2011, 165, 225-231.	3.7	59
67	Metabolic Profile in Growth Hormone-Deficient (GHD) Adults after Long-Term Recombinant Human Growth Hormone (rhGH) Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 352-361.	3.6	57
68	Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. <i>European Journal of Endocrinology</i> , 2016, 174, 355-362.	3.7	56
69	Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. <i>Growth Hormone and IGF Research</i> , 2010, 20, 226-233.	1.1	54
70	Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. <i>Clinical Endocrinology</i> , 2012, 77, 99-105.	2.4	54
71	Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3785-e3797.	3.6	54
72	A long-term follow-up study of eighteen patients with thyrotrophin-secreting pituitary adenomas. <i>Clinical Endocrinology</i> , 2014, 80, 395-402.	2.4	52

#	ARTICLE	IF	CITATIONS
73	Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL. <i>Pituitary</i> , 2015, 18, 86-100.	2.9	51
74	Bone material strength index as measured by impact microindentation is altered in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2017, 176, 339-347.	3.7	51
75	Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. <i>Pituitary</i> , 2007, 10, 237-249.	2.9	50
76	Patients Previously Treated for Nonfunctioning Pituitary Macroadenomas Have Disturbed Sleep Characteristics, Circadian Movement Rhythm, and Subjective Sleep Quality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1524-1532.	3.6	50
77	GH replacement therapy in elderly GH-deficient patients: a systematic review. <i>European Journal of Endocrinology</i> , 2011, 164, 657-665.	3.7	50
78	Postoperative diabetes insipidus: how to define and grade this complication?. <i>Pituitary</i> , 2021, 24, 284-291.	2.9	50
79	Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. <i>Clinical Endocrinology</i> , 2004, 60, 568-575.	2.4	49
80	Influence of the d3-Growth Hormone (GH) Receptor Isoform on Short-Term and Long-Term Treatment Response to GH Replacement in GH-Deficient Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2828-2834.	3.6	49
81	Long-Term Follow-Up Results of Postoperative Radiotherapy in 36 Patients with Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2476-2482.	3.6	49
82	Measurement of interleukin 10 in bronchoalveolar lavage from preterm ventilated infants. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2000, 82, 156F-159.	2.8	48
83	The effects of high fat diet on the basal activity of the hypothalamusâ€“pituitaryâ€“adrenal axis in mice. <i>Journal of Endocrinology</i> , 2012, 214, 191-197.	2.6	48
84	Ten-Year Follow-Up Results of Transsphenoidal Microsurgery in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4596-4602.	3.6	48
85	Acromegaly Is Associated with an Increased Prevalence of Colonic Diverticula: A Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2073-2079.	3.6	46
86	Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. <i>European Journal of Endocrinology</i> , 2012, 167, 235-244.	3.7	46
87	A single night of sleep curtailment increases plasma acylcarnitines: Novel insights in the relationship between sleep and insulin resistance. <i>Archives of Biochemistry and Biophysics</i> , 2016, 589, 145-151.	3.0	45
88	Disruption of circadian rhythm by alternating lightâ€“dark cycles aggravates atherosclerosis development in APOE*3â€“Leiden.CETP mice. <i>Journal of Pineal Research</i> , 2020, 68, e12614.	7.4	45
89	Resting-State Functional Connectivity in Patients with Long-Term Remission of Cushingâ€™s Disease. <i>Neuropsychopharmacology</i> , 2015, 40, 1888-1898.	5.4	44
90	Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. <i>European Journal of Endocrinology</i> , 2006, 155, 701-708.	3.7	43

#	ARTICLE	IF	CITATIONS
91	Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 320-325.	0.9	43
92	Six Months of Recombinant Human GH Therapy in Patients with Ischemic Cardiac Failure Does Not Influence Left Ventricular Function and Mass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4638-4643.	3.6	42
93	Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. <i>Clinical Endocrinology</i> , 2003, 58, 288-295.	2.4	42
94	Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 286, E25-E30.	3.5	41
95	Altered neural processing of emotional faces in remitted Cushing's disease. <i>Psychoneuroendocrinology</i> , 2015, 59, 134-146.	2.7	40
96	Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. <i>European Journal of Endocrinology</i> , 2016, 174, 651-662.	3.7	40
97	Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly. <i>Pituitary</i> , 2009, 12, 339-346.	2.9	39
98	Enhanced self-efficacy after a self-management programme in pituitary disease: a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2017, 177, 59-72.	3.7	38
99	Patients cured from craniopharyngioma or nonfunctioning pituitary macroadenoma (NFMA) suffer similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls. <i>Clinical Endocrinology</i> , 2008, 69, 769-774.	2.4	33
100	Increased aortic root diameters in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2008, 159, 97-103.	3.7	33
101	The Exon-3 Deleted Growth Hormone Receptor Polymorphism Predisposes to Long-Term Complications of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4671-4678.	3.6	33
102	Diminished and irregular TSH secretion with delayed acrophase in patients with Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2009, 161, 695-703.	3.7	33
103	Alterations in diurnal rhythmicity in patients treated for nonfunctioning pituitary macroadenoma: a controlled study and literature review. <i>European Journal of Endocrinology</i> , 2014, 171, 217-228.	3.7	33
104	Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. <i>Growth Hormone and IGF Research</i> , 2005, 15, 200-206.	1.1	32
105	Pretreatment Insulin-Like Growth Factor-I Concentrations Predict Radiographic Osteoarthritis in Acromegalic Patients with Long-Term Cured Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2374-2379.	3.6	32
106	Drawings Reflect a New Dimension of the Psychological Impact of Long-Term Remission of Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3123-3131.	3.6	32
107	Work disability and its determinants in patients with pituitary tumor-related disease. <i>Pituitary</i> , 2018, 21, 593-604.	2.9	31
108	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa205.	0.2	31

#	ARTICLE	IF	CITATIONS
109	The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary. <i>Pituitary</i> , 2016, 19, 293-302.	2.9	30
110	IGSF1 deficiency syndrome. <i>Rare Diseases (Austin, Tex)</i> , 2013, 1, e24883.	1.8	29
111	Effects of up to 15 years of recombinant human <sc>GH</sc> (rh<sc>GH</sc>) replacement on bone metabolism in adults with Growth Hormone Deficiency (<sc>GHD</sc>): The Leiden Cohort Study. <i>Clinical Endocrinology</i> , 2014, 81, 727-735.	2.4	29
112	Pituitary dysfunction in adult patients after cranial irradiation for head and nasopharyngeal tumours. <i>Radiotherapy and Oncology</i> , 2014, 113, 102-107.	0.6	29
113	How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review. <i>Pituitary</i> , 2018, 21, 208-216.	2.9	29
114	Thyrotropin Secretion in Healthy Subjects Is Robust and Independent of Age and Gender, and Only Weakly Dependent on Body Mass Index. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 570-578.	3.6	28
115	Spatial and temporal expression of immunoglobulin superfamily member 1 in the rat. <i>Journal of Endocrinology</i> , 2015, 226, 181-191.	2.6	28
116	Pituitary Magnetic Resonance Imaging Is Not Required in the Postoperative Follow-Up of Acromegalic Patients with Long-Term Biochemical Cure after Transsphenoidal Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4320-4324.	3.6	27
117	Costâ€ effectiveness of lanreotide Autogel^{Â®} in treatment algorithms of acromegaly. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 223-234.	1.4	27
118	Patients With Adrenal Insufficiency Hate Their Medication: Concerns and Stronger Beliefs About the Necessity of Hydrocortisone Intake Are Associated With More Negative Illness Perceptions. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3668-3676.	3.6	27
119	Timeâ€ and stateâ€ dependent analysis of autonomic control in narcolepsy: higher heart rate with normal heart rate variability independent of sleep fragmentation. <i>Journal of Sleep Research</i> , 2015, 24, 206-214.	3.2	27
120	Chronic Central Serous Chorioretinopathy as a Presenting Symptom of Cushing Syndrome. <i>European Journal of Ophthalmology</i> , 2016, 26, 442-448.	1.3	27
121	New medical therapies on the horizon: oral octreotide. <i>Pituitary</i> , 2017, 20, 149-153.	2.9	27
122	Health-related quality of life of cranial WHO grade I meningioma patients: are current questionnaires relevant?. <i>Acta Neurochirurgica</i> , 2017, 159, 2149-2159.	1.7	27
123	Improvement but no normalization of quality of life and cognitive functioning after treatment for Cushingâ€™s syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5325-5337.	3.6	27
124	Diminished and Irregular Thyrotropin Secretion with Preserved Diurnal Rhythm in Patients with Active Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1945-1950.	3.6	26
125	The burden of disease for pituitary patients. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101309.	4.7	26
126	Additional Beneficial Effects of Alendronate in Growth Hormone (GH)-Deficient Adults with Osteoporosis Receiving Long-Term Recombinant Human GH Replacement Therapy: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3079-3085.	3.6	25

#	ARTICLE	IF	CITATIONS
127	Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study. <i>Pituitary</i> , 2014, 17, 44-52.	2.9	25
128	Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly. <i>European Journal of Endocrinology</i> , 2005, 153, 231-238.	3.7	24
129	Pharmacologic Therapies for Acromegaly. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2005, 4, 43-53.	1.8	24
130	Current pharmacotherapy for acromegaly: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2393-2405.	1.8	24
131	Mild cognitive deficits in patients with primary adrenal insufficiency. <i>Psychoneuroendocrinology</i> , 2016, 63, 170-177.	2.7	24
132	Microscopic versus endoscopic transsphenoidal surgery in the Leiden cohort treated for Cushing's disease: surgical outcome, mortality, and complications. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 64.	2.7	24
133	Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. <i>European Journal of Endocrinology</i> , 2005, 152, 53-60.	3.7	23
134	Effects of High Fat Diet on the Basal Activity of the Hypothalamus-Pituitary-Adrenal Axis in Mice: A Systematic Review. <i>Hormone and Metabolic Research</i> , 2011, 43, 899-906.	1.5	23
135	Determinants of Altered Sleep-Wake Rhythmicity in Patients Treated for Nonfunctioning Pituitary Macroadenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4497-4505.	3.6	23
136	Growth Hormone (GH) Secretion in Patients with an Inactivating Defect of the GH-Releasing Hormone (GHRH) Receptor Is Pulsatile: Evidence for a Role for Non-GHRH Inputs into the Generation of GH Pulses. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2459-2464.	3.6	23
137	Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 102-111.	11.4	23
138	Long-term effects of glucocorticoid excess on the brain. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	2.6	23
139	Stimulatory Effect of Insulin on Glucose Uptake by Muscle Involves the Central Nervous System in Insulin-Sensitive Mice. <i>Diabetes</i> , 2011, 60, 3132-3140.	0.6	22
140	Pituitary Hormone Secretion Profiles in IGSF1 Deficiency Syndrome. <i>Neuroendocrinology</i> , 2016, 103, 408-416.	2.5	22
141	Cushing's Syndrome and Hypothalamic-Pituitary-Adrenal Axis Hyperactivity in Chronic Central Serous Chorioretinopathy. <i>Frontiers in Endocrinology</i> , 2018, 9, 39.	3.5	22
142	IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e70-e84.	3.6	22
143	Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly. <i>Clinical Endocrinology</i> , 2002, 56, 313-319.	2.4	21
144	Persistent negative illness perceptions despite long-term biochemical control of acromegaly: novel application of the drawing test. <i>European Journal of Endocrinology</i> , 2015, 172, 583-593.	3.7	21

#	ARTICLE	IF	CITATIONS
145	Increased Hair Cortisol Concentrations and BMI in Patients With Pituitary-Adrenal Disease on Hydrocortisone Replacement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2456-2462.	3.6	21
146	Pre-operative serum inflammation-based scores in patients with pituitary adenomas. <i>Pituitary</i> , 2021, 24, 334-350.	2.9	21
147	Nanomedicines in the treatment of acromegaly: focus on pegvisomant. <i>International Journal of Nanomedicine</i> , 2006, 1, 385-398.	6.7	21
148	GH deficiency in patients irradiated for acromegaly: significance of GH stimulatory tests in relation to the 24 h GH secretion. <i>European Journal of Endocrinology</i> , 2006, 154, 851-858.	3.7	20
149	Treatment of nonfunctioning pituitary adenomas: What were the contributions of the last 10years? A critical view. <i>Annales D'Endocrinologie</i> , 2012, 73, 111-116.	1.4	20
150	Mild deficits in attentional control in patients with the <sc>IGSF</sc>1 deficiency syndrome. <i>Clinical Endocrinology</i> , 2016, 84, 896-903.	2.4	20
151	Pulsatile, nyctohemeral and entropic characteristics of GH secretion in adult GH-deficient patients: selectively decreased pulsatile release and increased secretory disorderliness with preservation of diurnal timing and gender distinctions. <i>Clinical Endocrinology</i> , 2002, 56, 79-87.	2.4	19
152	Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms. <i>European Journal of Endocrinology</i> , 2012, 166, 407-413.	3.7	19
153	IGSF1 variants in boys with familial delayed puberty. <i>European Journal of Pediatrics</i> , 2015, 174, 687-692.	2.7	19
154	More concerns and stronger beliefs about the necessity of medication in patients with acromegaly are associated with negative illness perceptions and impairment in quality of life. <i>Growth Hormone and IGF Research</i> , 2015, 25, 219-226.	1.1	19
155	Familial longevity is characterized by high circadian rhythmicity of serum cholesterol in healthy elderly individuals. <i>Aging Cell</i> , 2017, 16, 237-243.	6.7	19
156	How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. <i>Pituitary</i> , 2018, 21, 310-322.	2.9	19
157	The partnerâ€™s perspective of the impact of pituitary disease: Looking beyond the patient. <i>Journal of Health Psychology</i> , 2019, 24, 1687-1697.	2.3	19
158	Improvement in Symptoms and Health-Related Quality of Life in Acromegaly Patients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 577-587.	3.6	19
159	Serum Inflammation-based Scores in Endocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3796-e3819.	3.6	19
160	Toward Value Based Health Care in pituitary surgery: application of a comprehensive outcome set in perioperative care. <i>European Journal of Endocrinology</i> , 2019, 181, 375-387.	3.7	19
161	Acromegalic arthropathy in various stages of the disease: an MRI study. <i>European Journal of Endocrinology</i> , 2017, 176, 779-790.	3.7	18
162	Maladaptive personality traits, psychological morbidity and coping strategies in chronic central serous chorioretinopathy. <i>Acta Ophthalmologica</i> , 2019, 97, e572-e579.	1.1	18

#	ARTICLE	IF	CITATIONS
163	The tale in evolution: clarity, consistency and consultation, not contradiction and confusion. <i>Pituitary</i> , 2020, 23, 476-477.	2.9	18
164	Feasibility, safety, and outcomes of a stratified fast-track care trajectory in pituitary surgery. <i>Endocrine</i> , 2020, 69, 175-187.	2.3	18
165	Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands. <i>Frontiers in Endocrinology</i> , 2021, 12, 627711.	3.5	18
166	Low Incidence of Adrenal Insufficiency after Transsphenoidal Surgery in Patients with Acromegaly: A Long-Term Follow-Up Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1163-E1170.	3.6	17
167	Time-restricted feeding improves adaptation to chronically alternating light-dark cycles. <i>Scientific Reports</i> , 2019, 9, 7874.	3.3	17
168	Endoscopic Surgery for Pituitary Tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 487-503.	3.2	17
169	Progression of acromegalic arthropathy in long-term controlled acromegaly patients: 9 years of longitudinal follow-up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 188-200.	3.6	17
170	Therapeutic options in the management of acromegaly: focus on lanreotide Autogel®. <i>Biologics: Targets and Therapy</i> , 2008, 2, 463.	3.2	16
171	Is IGSF1 involved in human pituitary tumor formation?. <i>Endocrine-Related Cancer</i> , 2015, 22, 47-54.	3.1	16
172	Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism. <i>European Journal of Endocrinology</i> , 2007, 157, 709-716.	3.7	15
173	High Prevalence of Metabolic Syndrome Features in Patients Previously Treated for Nonfunctioning Pituitary Macroadenoma. <i>PLoS ONE</i> , 2014, 9, e90602.	2.5	15
174	Quality of life in patients with adrenal insufficiency correlates stronger with hydrocortisone dosage, than with long-term systemic cortisol levels. <i>Psychoneuroendocrinology</i> , 2016, 72, 80-86.	2.7	15
175	Pituitary-hormone secretion by thyrotropinomas. <i>Pituitary</i> , 2009, 12, 200-210.	2.9	14
176	Two phenotypes of arthropathy in long-term controlled acromegaly? A comparison between patients with and without joint space narrowing (JSN). <i>Growth Hormone and IGF Research</i> , 2013, 23, 159-164.	1.1	14
177	The Association between Habitual Sleep Duration and Sleep Quality with Glycemic Traits: Assessment by Cross-Sectional and Mendelian Randomization Analyses. <i>Journal of Clinical Medicine</i> , 2019, 8, 682.	2.4	14
178	Associations of sleep duration and quality with serum and hepatic lipids: The Netherlands Epidemiology of Obesity Study. <i>Journal of Sleep Research</i> , 2019, 28, e12776.	3.2	14
179	Early postoperative HPA-axis testing after pituitary tumor surgery: reliability and safety of basal cortisol and CRH test. <i>Endocrine</i> , 2020, 67, 161-171.	2.3	14
180	Investigating the relationships between unfavourable habitual sleep and metabolomic traits: evidence from multi-cohort multivariable regression and Mendelian randomization analyses. <i>BMC Medicine</i> , 2021, 19, 69.	5.5	14

#	ARTICLE	IF	CITATIONS
181	Both Transient and Continuous Corticosterone Excess Inhibit Atherosclerotic Plaque Formation in APOE*3-Leiden.CETP Mice. PLoS ONE, 2013, 8, e63882.	2.5	14
182	The incidence of adrenal crisis in the postoperative period of HPA axis insufficiency after surgical treatment for Cushing's syndrome. European Journal of Endocrinology, 2019, 181, 201-210.	3.7	14
183	Sex Differences in Presentation but Not in Outcome for ACTH-Dependent Cushing's Syndrome. Frontiers in Endocrinology, 2019, 10, 580.	3.5	13
184	A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 883-891.	3.6	13
185	Multi-ancestry genome-wide gene-sleep interactions identify novel loci for blood pressure. Molecular Psychiatry, 2021, 26, 6293-6304.	7.9	13
186	Treatment strategies for acromegaly. Expert Opinion on Emerging Drugs, 2005, 10, 875-890.	2.4	12
187	The use of an early postoperative CRH test to assess adrenal function after transsphenoidal surgery for pituitary adenomas. Pituitary, 2012, 15, 436-444.	2.9	12
188	Glucocorticoid excess induces long-lasting changes in body composition in male C57Bl/6J mice only with high-fat diet. Physiological Reports, 2013, 1, e00103.	1.7	12
189	Mapping AcroQoL scores to EQ-5D to obtain utility values for patients with acromegaly. Journal of Medical Economics, 2018, 21, 382-389.	2.1	12
190	A physiological glucocorticoid rhythm is an important regulator of brown adipose tissue function. Molecular Metabolism, 2021, 47, 101179.	6.5	12
191	Habitual Sleep Measures are Associated with Overall Body Fat, and not Specifically with Visceral Fat, in Men and Women. Obesity, 2018, 26, 1651-1658.	3.0	11
192	Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results. Pituitary, 2021, 24, 943-953.	2.9	11
193	Role of radiotherapy in the management of acromegaly. Expert Review of Endocrinology and Metabolism, 2006, 1, 449-460.	2.4	10
194	Unexpected concomitant pituitary adenoma and suprasellar meningioma: a case report and review of the literature. British Journal of Neurosurgery, 2023, 37, 677-681.	0.8	10
195	SF-12 or SF-36 in pituitary disease? Toward concise and comprehensive patient-reported outcomes measurements. Endocrine, 2020, 70, 123-133.	2.3	10
196	Central serous chorioretinopathy in active endogenous Cushing's syndrome. Scientific Reports, 2021, 11, 2748.	3.3	10
197	Additional Beneficial Effects of Alendronate in Growth Hormone (GH)-Deficient Adults with Osteoporosis Receiving Long-Term Recombinant Human GH Replacement Therapy: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3079-3085.	3.6	10
198	Efficacy of needle-free administration of recombinant human growth hormone in adults with growth hormone deficiency. British Journal of Clinical Pharmacology, 2006, 61, 451-455.	2.4	9

#	ARTICLE	IF	CITATIONS
199	The role of pegvisomant in the treatment of acromegaly. Expert Opinion on Biological Therapy, 2008, 8, 691-704.	3.1	9
200	Hormone Secretion by Pituitary Adenomas Is Characterized by Increased Disorderliness and Spikiness but More Regular Pulsing. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3836-3844.	3.6	9
201	Effects of discontinuation of growth hormone replacement in adult GH-deficient patients: a cohort study and a systematic review of the literature. European Journal of Endocrinology, 2016, 174, 705-716.	3.7	9
202	Healthcare utilization and costs among patients with non-functioning pituitary adenomas. Endocrine, 2019, 64, 330-340.	2.3	9
203	An overview of clinical activities in Endo-ERN: the need for alignment of future network criteria. European Journal of Endocrinology, 2020, 183, 141-148.	3.7	9
204	State of the Art of Patient-reported Outcomes in Acromegaly or GH Deficiency: A Systematic Review and Meta-analysis. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1225-1238.	3.6	9
205	Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. Pituitary, 2022, 25, 587-601.	2.9	9
206	Six-months of recombinant human GH therapy in patients with ischemic cardiac failure. International Journal of Cardiovascular Imaging, 2004, 20, 53-60.	1.5	8
207	Optimizing Blood Sampling Protocols in Patients With Acromegaly for the Estimation of Growth Hormone Secretion. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2675-2682.	3.6	8
208	Clinical Unmet Needs in the Treatment of Adrenal Crisis: Importance of the Patient's Perspective. Frontiers in Endocrinology, 2021, 12, 701365.	3.5	8
209	Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature. European Journal of Endocrinology, 2021, 185, 99-108.	3.7	8
210	Abnormal metabolic phenotype in middle-aged GH-deficient adults despite long-term recombinant human GH replacement. European Journal of Endocrinology, 2014, 170, 263-272.	3.7	7
211	Quality of care evaluation in non-functioning pituitary adenoma with chiasm compression: visual outcomes and timing of intervention clinical recommendations based on a systematic literature review and cohort study. Pituitary, 2020, 23, 417-429.	2.9	7
212	Outcome Squares Integrating Efficacy and Safety, as Applied to Functioning Pituitary Adenoma Surgery. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3300-e3311.	3.6	7
213	The PRolaCT studies "A study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma. Trials, 2021, 22, 653.	1.6	7
214	Mortality in acromegaly reduced with multimodal therapy. Nature Reviews Endocrinology, 2014, 10, 708-710.	9.6	6
215	Unmet needs and recommendations to improve meningioma care through patient, partner, and health care provider input: a mixed-method study. Neuro-Oncology Practice, 2020, 7, 239-248.	1.6	6
216	New consensus in acromegaly: criteria for cure and control. Nature Reviews Endocrinology, 2010, 6, 480-481.	9.6	5

#	ARTICLE	IF	CITATIONS
217	Relationship between the functional exon 3 deleted growth hormone receptor polymorphism and symptomatic osteoarthritis in women. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 433-436.	0.9	5
218	Total score or subscales in scoring the acromegaly quality of life questionnaire: using novel confirmatory methods to compare scoring options. <i>European Journal of Endocrinology</i> , 2015, 173, 37-42.	3.7	5
219	Decrease in scale invariance of activity fluctuations with aging and in patients with suprasellar tumors. <i>Chronobiology International</i> , 2018, 35, 368-377.	2.0	5
220	Hair cortisol concentrations in chronic central serous chorioretinopathy. <i>Acta Ophthalmologica</i> , 2020, 98, 390-395.	1.1	5
221	Healthcare utilization and costs among prolactinoma patients: a cross-sectional study and analysis of determinants. <i>Pituitary</i> , 2021, 24, 79-95.	2.9	5
222	Conditioning cortisol in healthy young women – A randomized controlled trial. <i>Psychoneuroendocrinology</i> , 2021, 124, 105081.	2.7	5
223	⁶⁸ Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 4.	1.5	5
224	Clinical and radiographic assessment of peripheral joints in controlled acromegaly. <i>Pituitary</i> , 2022, 25, 622-635.	2.9	5
225	Outcome of complications in acromegaly patients after long-term disease remission. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 499-510.	2.4	4
226	Continuous Light Does Not Affect Atherosclerosis in APOE*3-Leiden.CETP Mice. <i>Journal of Biological Rhythms</i> , 2020, 35, 598-611.	2.6	4
227	Response to Letter to the Editor: “Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis” <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3040-e3041.	3.6	4
228	Longitudinal assessment of response to treatment with oral octreotide capsules in patients with acromegaly: post-hoc analysis of a phase 3 trial. <i>Endocrine Abstracts</i> , 0, , .	0.0	4
229	Impact of patient-reported nasal symptoms on quality of life after endoscopic pituitary surgery: a prospective cohort study. <i>Pituitary</i> , 2022, 25, 308-320.	2.9	4
230	The Role of the Suprachiasmatic Nucleus in Cardiac Autonomic Control during Sleep. <i>PLoS ONE</i> , 2016, 11, e0152390.	2.5	3
231	Pituitary Adenoma Apoplexy in an Adolescent: A Case Report and Review of the Literature. <i>JCRPE Journal of Clinical Research in Pediatric Endocrinology</i> , 2017, 9, 265-273.	0.9	3
232	Chiasmal herniation following treatment of pituitary macroadenoma. <i>Pituitary</i> , 2021, 24, 68-78.	2.9	3
233	A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands. <i>Journal of the Endocrine Society</i> , 2021, 5, A517-A517.	0.2	3
234	Low prevalence of neuropathic-like pain symptoms in long-term controlled acromegaly. <i>Pituitary</i> , 2022, 25, 229-237.	2.9	3

#	ARTICLE	IF	CITATIONS
235	The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone. <i>BMJ Open</i> , 2021, 11, e054405.	1.9	3
236	Testosterone in men with hypogonadism and transgender males: a systematic review comparing three different preparations. <i>Endocrine Connections</i> , 2022, 11, .	1.9	3
237	Mild cognitive deficits in patients on stable treatment for primary adrenal insufficiency. <i>Psychoneuroendocrinology</i> , 2015, 61, 46.	2.7	2
238	Understanding and predicting fracture risk in acromegaly. <i>Endocrine</i> , 2017, 55, 662-663.	2.3	2
239	The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a ⁶⁸ Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size. <i>BMJ Open</i> , 2020, 10, e038250.	1.9	2
240	Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy. <i>Journal of the Endocrine Society</i> , 2021, 5, A518-A519.	0.2	2
241	Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial. <i>Journal of the Endocrine Society</i> , 2021, 5, A520-A521.	0.2	2
242	Low sclerostin levels after long-term remission of acromegaly. <i>Endocrine</i> , 2022, 75, 228-238.	2.3	2
243	IGF-1 and IGF-1 SDS “fit for purpose?”. <i>European Journal of Endocrinology</i> , 2019, 181, L1-L4.	3.7	2
244	Progression of vertebral fractures in long-term controlled acromegaly: A 9-year follow-up study. <i>Endocrine Abstracts</i> , 0, , .	0.0	2
245	Illness perceptions, risk perception and worry in SDH mutation carriers. <i>Familial Cancer</i> , 2014, 13, 83-91.	1.9	1
246	Effect of anthelmintic treatment on serum free IGF-1 and IGFBP-3: a cluster-randomized-controlled trial in Indonesia. <i>Scientific Reports</i> , 2020, 10, 19023.	3.3	1
247	Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 348.	11.4	1
248	Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly. <i>Journal of the Endocrine Society</i> , 2021, 5, A527-A528.	0.2	1
249	Costs and Its Determinants in Pituitary Tumour Surgery. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	1
250	Lanreotide Autogel® in the Treatment of Acromegaly. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2150.	0.1	0
251	Mapping Acroqol Scores to EQ-5D to Obtain Utility Values for Patients with Acromegaly. <i>Value in Health</i> , 2017, 20, A484.	0.3	0
252	Disruption of the biological clock aggravates atherosclerosis. <i>Atherosclerosis</i> , 2018, 275, e13-e14.	0.8	0

#	ARTICLE	IF	CITATIONS
253	Associations between measures of sleep with serum and hepatic lipid profile: The Netherlands epidemiology of obesity study. <i>Atherosclerosis</i> , 2018, 275, e77.	0.8	0
254	Disruption Of The Biological Clock Affects Immune Homeostasis And Aggravates Atherosclerosis Development. <i>Atherosclerosis</i> , 2019, 287, e16.	0.8	0
255	Response to Letter to the Editor: "GDF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction" <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2315-e2316.	3.6	0
256	Osteoporosis and arthropathy in functioning pituitary tumors. , 2021, , 617-637.		0
257	Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands"Results From the MPOWERED Trial. <i>Journal of the Endocrine Society</i> , 2021, 5, A522-A523.	0.2	0
258	The use of e-REC for capturing the occurrence of covid-19 infections in people with rare endocrine conditions. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
259	MON-LB55 Biochemical Control of Most Patients Reverting to Injectable Long-Acting Somatostatin Receptor Ligands Is Achieved After One Dose: Results From the Phase 3, Randomized, Double Blind, Placebo-Controlled Optimal Study. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
260	MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
261	MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
262	Opioids and their endocrine effects: A systematic review and meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	3.6	0
263	Opioids and their endocrine effects: A systematic review and meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	3.6	0